Evofem Biosciences, Inc. · OTC:EVFM
Evofem Biosciences — Investor Presentation (September 2021)
22 slides from Evofem Biosciences's investor presentation, Sep 10, 2021
Slide 1: Revolutionizing Women's Sexual and Reproductive Health
Revolutionizing Women’s Sexual and Reproductive Health September 2021 NASDAQ: EVFM evofem.com © 2021 Evofem Biosciences, Inc. | For investor discussions only.
Slide 2: Forward-Looking Statements
© 2021 Evofem Biosciences, Inc. | For investor discussions only. Page | 2 Forward-Looking Statements This presentation contains forward looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 and other federal securities laws. In some cases, you can identify for
Slide 3: Evofem Biosciences investment highlights
© 2021 Evofem Biosciences, Inc. | For investor discussions only. Page | 3 Multi-billion $$ addressable U.S. market opportunity for current and late-stage investigational indications Shattering the hormone glass ceiling with hormone-free, on-demand prescription contraceptive vaginal gel Top-line data
Slide 4: An Innovative Prescription Contraceptive
© 2021 Evofem Biosciences, Inc. | For investor discussions only. Page | 4 An Innovative Prescription Contraceptive • FDA-approved for the prevention of pregnancy • Hormone-free • Applied 0-60 minutes before each act of sex • Box of 12 pre-filled applicators
Slide 5: Vaginal pH Modulator MOA
© 2021 Evofem Biosciences, Inc. | For investor discussions only. Page | 5 Vaginal pH Modulator MOA When semen (pH 7.1 - 8) enters the vagina, it raises the environmental pH level • Allows sperm to be mobile and swim up the reproductive canal Phexxi works to keep vaginal pH in the baseline range Vagi
Slide 6: $1.5B – $2.4B U.S. Opportunity
© 2021 Evofem Biosciences, Inc. | For investor discussions only. Page | 6 $1.5B – $2.4B U.S. Opportunity U.S. CONTRACEPTIVE COMMERCIAL OPPORTUNITY 1. Daniels K, Abma JC. Current contraceptive status among women aged 15-49: United States, 2015-2017. NCHS Data Brief. 2018; 327: 1-14. 2. Example market
Slide 7: Strong Quarter over Quarter Growth: Prescriptions and Dispensed Units
© 2021 Evofem Biosciences, Inc. | For investor discussions only. Page | 7 Strong Quarter over Quarter Growth: Prescriptions and Dispensed Units Source: IQVIA (including Knipper) monthly data; excludes 340b/VA dispenses Note: Some Phexxi prescriptions are for more than one unit 65% INCREASE IN DISPEN
Slide 8: Strong Quarter over Quarter Growth: Phexxi Prescriber Base
© 2021 Evofem Biosciences, Inc. | For investor discussions only. Page | 8 CUMULATIVE PHEXXI PRESCRIBERS OVER 8,600 HCPS HAVE PRESCRIBED PHEXXI FROM LAUNCH THROUGH AUGUST 20, 2021 Strong Quarter over Quarter Growth: Phexxi Prescriber Base Source: XPO Dispensed NRx by HCP, including Knipper and exclud
Slide 9: User Demographics
© 2021 Evofem Biosciences, Inc. | For investor discussions only. Page | 9 User Demographics • 49% were not on a method of contraception in the past year • 29% switching from oral contraceptives • 7% switching from hormonal rings and patches Age demographic: early 20s to 35 No Contraception 49% Oral
Slide 10: Phexxi for Cancer Patients
© 2021 Evofem Biosciences, Inc. | For investor discussions only. Page | 10 Phexxi for Cancer Patients WHY • ~800,000 new cancer cases reported annually among women1 • Many women with cancer are contraindicated to hormones • Phexxi uniquely offers hormone-free, non-invasive prescription contraception
Slide 11: My Story Amy Rules
— a MY STORY AMY RULES. [ y —_ | ~~
Slide 12: Testimonial: Tell Hormones to Take a Hike
Testimonial TELL HORMONES TO TAKE A HIKE.
Slide 13: Annie Murphy's Journey to Finding Phexxi
Annie Murphy’s Journey to Finding Phexxi To view Annie Murphy’s Phexxi story, please visit https://www.phexxi.com/annie-murphy
Slide 14: Annie Murphy x Phexxi commercial
To view the :60 Annie Murphy x Phexxi commercial please visit https://www.phexxi.com/annie-murphy
Slide 15: House Rules will Extend through a Full Omni-Channel Rollout
House Rules will Extend through a Full Omni-Channel Rollout Campaign Videos ●:60 & :45 second commercial ●Annie’s personal birth control testimonial video Online Video Series ●:15 videos focused on Phexxi House Rules for online and social channels Social Media ●Phexxi social media organic content ●P
Slide 16: Increase Access through ACA
© 2021 Evofem Biosciences, Inc. | For investor discussions only. Page | 16 I. Increase Access through ACA Affordable Care Act (ACA) currently mandates 18 specific methods of contraception be covered without any out-of- pocket costs Aggressively advancing strategy to gain new “vaginal pH modulator” c
Slide 17: Current Reimbursement
© 2021 Evofem Biosciences, Inc. | For investor discussions only. Page | 17 Current Reimbursement OVER 65% of prescriptions currently covered 100% of Medicaid recipients have access to Phexxi through National Drug Rebate agreement Medi-Cal (California) added Phexxi to a preferred drug position Covere
Slide 18: Expand Global Reach: ex-U.S. Licenses
© 2021 Evofem Biosciences, Inc. | For investor discussions only. Page | 18 Expand Global Reach: ex-U.S. Licenses • Discussions underway with potential licensees for commercialization of Phexxi in multiple international markets • Anticipated structure: - Upfront capital - Milestone payments - Tiered
Slide 19: Successfully Develop EVO100 for STI Prevention
© 2021 Evofem Biosciences, Inc. | For investor discussions only. Page | 19 Successfully Develop EVO100 for STI Prevention • Goal – expand Phexxi label to include prevention of urogenital chlamydia and gonorrhea in women • Ongoing pivotal Phase 3 trial builds on highly positive Phase 2B/3 trial1 1. C
Slide 20: Opportunity: Prevention of Chlamydia & Gonorrhea
© 2021 Evofem Biosciences, Inc. | For investor discussions only. Page | 20 Opportunity: Prevention of Chlamydia & Gonorrhea 1. US Centers for Disease Control and Prevention (2019): CDC detailed fact sheet on gonorrhea and CDC detailed fact sheet on chlamydia 2. Daniels K, Abma JC. Current contracept
Slide 21: Breaking the Hormone Glass Ceiling
© 2021 Evofem Biosciences, Inc. | For investor discussions only. Page | 21 Breaking the Hormone Glass Ceiling Additional value creating opportunities Phexxi: hormone-free prescription contraception women control and use only when needed Aggressively pursuing ACA strategy Advancing ex-U.S. partnershi
Slide 22: Thank You
1.858.550.1900 ir@evofem.com 12400 High Bluff Drive, Suite 600 San Diego, California 92130 NASDAQ: EVFM evofem.com Thank You
Evofem Biosciences — Investor Presentation (September 2021) on 6ix